Jeff founded Apeiron Partners in 1996 and has structured a variety of strategic alliances, financings and, particularly, corporate spin-outs and other NewCos. Jeff has designed and completed five such NewCos to date, including Targacept, Inc. (NASD:TRGT) from the R.J. Reynolds Tobacco Company, Artisan Pharma, Inc., Ketocytonyx from BTG, Plc., QED Solutions, Inc., and KBI BIoPharma, Inc. from Kinetic BioSystems, Inc.. In addition, Jeff worked extensively on the design and structuring of BioCritica, Inc. from Eli Lilly & Company.
Between 2005 – 2009, Jeff advised Asahi Kasei Pharma Corporation in establishing and financing Artisan Pharma, Inc., involving a product that is now marketed in Japan (ART 123). As its founding CEO, Jeff raised over $50 million, built a full operational team and led all strategic and tactical initiatives.
Between 2003 – 2006 Jeff and the Apeiron team were selected as advisors to Z-Cube s.r.l., the corporate venture arm of Zambon Group, s.r.l., the largest privately-held pharmaceutical company in Italy, to assist it in establishing and investing a €60 million fund. As a result, he played a significant role in identifying and structuring investments in Suppremol, GmbH, Pharmeste, s.r.l., and others.
Prior to Apeiron, Jeff worked for Medical Science Partners (MSP), a Harvard-affiliated venture capital fund, and was intimately involved in the business development of a number of its portfolio companies. These firms spanned start-ups through publicly-held companies and included deCode Genetics, ICAgen, Diatide, Zycos and Oravax, amongst others.
Prior to MSP, Jeff was Executive Director of Business Development for the life sciences group of a trading company affiliate of the Bank of Tokyo-Mitsubishi, where he was responsible for a number of strategic alliances between U.S. and Japanese firms.
Jeff received his M.D. from Rush Medical College in Chicago and his MBA from the University of Chicago.
Direct: +1 508.400.1856